Failure of an immunometric assay to detect elevated creatine kinase MB isoenzyme
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is a well-established procedure for the diagnosis and management of myocardial infarction.' Available methods for CK-MB determination include electrophoresis with quantification by densitometry and assays measuring residual CK activity following inhibition or precipitation of the M subunit by antibodies. However, interference from CK variants can occur-as the polyclonal antibodies are directed against M subunits. Newer immunometric assays measuring CK-MB concentration rather than activity improve specificity by using monoclonal antibodies (Mab) that recognize the M and B subunits or the M-B bridge region.? Erroneously elevated CK-MB values are eliminated because cross-reactivity with other CK variants is negligible." We report the following case in which an immunometric assay for CK-MB (Novo Nordisk Diagnostics, Cambridge, UK) displayed erroneously low CK-MB levels in a patient investigated for possible myocardial infarction.
CLINICAL CASE
A 74-year-old female with a history of collapse and atypical chest pain of 3 h duration was admitted to the coronary care unit with a diagnosis of unstable angina. The admission electrocardiogram (ECG) showed ST elevation which was non-progressive and serum electrolytes and CK-MB mass concentration were normal (day 1). The patient was initially managed with intravenous nitrates but following an episode of severe chest pain during the evening of day 2 Correspondence: Dr R T Peaston, streptokinase was administered intravenously as a myocardial infarction was strongly suspected. The pain eventually settled and she had an episode of fast atrial fibrillation for which she was digitalized (day 3). Serum CK-MB concentrations were measured for seven consecutive days from admission by an immunoenzymometric assay (lEMA) in accordance with the manufacturer's protocol (Novo Nordisk Diagnostics) using a twosite lEMA with murine Mab directed against the CK-M and CK-B subunits. All CK-MB results for this patient were less than the detection limit of 2· 0 ",giL (Table 1) .
RESULTS AND DISCUSSION
When the patient samples were assayed for total CK at 37°C (CK NAC, Roche Products, Welwyn Garden City, UK) and CK-MB activity at 37°C by the Roche Isomune procedure (immunoinhibition/immunoprecipitation) on a centrifugal analyser (Cobas Bio, Roche Products, UK), abnormal results were obtained (Table 1) . Agarose gel electrophoresis with densitometric scanning (Ciba-Corning Diagnostics, Halstead, UK) further confirmed the increased CK-MB fraction in samples from days 4 and 5. Dilution and repeat analysis of all samples by the immunometric assay did not resolve the low results obtained. Rheumatoid factor or monoclonal paraprotein were not detected in the samples.
Interference from heterophilic antibodies in assays using monoclonal antibodies is now well recognized but generally leads to erroneously increased values." To assess whether the interference was due to the presence of circulating antibodies to animal immunoglobulins, the samples were re-assayed by the Novo procedure in the presence of mouse serum. As controls, four patient samples with a range of CK-MB values were also re-assayed. Mouse serum failed to abolish the apparent suppression of the CK-MB binding sequence with this patient. In addition, adding mouse serum to the conjugate reagent or changing the assay protocol to a two-stage incubation procedure with sequential washing between each stage did not resolve the apparent falsely low CK-MB values for this patient.
In order to determine whether the discrepancies between the immunoinhibition and the immunometric procedures were due to the use of polyclonal or monoclonal antibodies, samples were assayed by an enzyme-linked immunosorbent assay, ELISA (Tandem-E, Hybritech, Nottingham, UK) using a similar sandwich reaction sequence of Mab-CK-B capture and alkaline phosphatase labelled anti-CK-MB. Results were in agreement with the immunoinhibition procedure (Table 1) . To establish if the samples contained constituents that may inhibit the Novo Biolabs peroxidase reaction sequence, CK-MB was measured by a luminescence immunometric procedure (Amerlite CK-MB, Amerlite Diagnostics, Buckinghamshire, UK) utilizing a Mab-CK-MB labelled with peroxidase that recognizes the M-B bridge region. A similar range of values was observed ( Table 1) . Further testing with another IEMA, (Stratus Baxter CK-MB, Baxter Healthcare, Egham, UK) using Mab-CK-MB and Mab-CK-BB labelled with alkaline phosphatase also demonstrated increased CK-MB results. Thus none of the alternative immunometric procedures showed the discrepant results apparent with the Novo Biolabs procedure.
A split assay was devised to determine if the capture Mab (anti-CK-B) in the Novo Biolabs method was displaying restricted reactivity with this individual. Following initial incubation with solely the Novo capture Mab, the well contents were then transferred to a set of Amerlite coated strips for CK-MB measurements. Results similar to the immunometric procedures with the exception of the NOVO IEMA were obtained. It appeared that either the monoclonal capture anti-body on the Novo wells was not recognizing the CK-B epitope of this patient or samples contained a constituent such as binding protein or peptide which masked the relevant B subunit epitope, preventing binding with the Novo Biolabs anti-CK-B capture antibody. Although recoveryexperiments with added CK-MB or addition of serum from this patient to other patient samples may have provided further insight, insufficient sample volume prevented further investigation.
